The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
AACR 2017 | Poster 3724/9 – PD-L1 protein expression and tumor mutation burden correlates with Hodgkin and Diffuse Large B-Cell Lymphoma
At the American Association for Cancer Research (AACR) annual meeting in Washington, DC, USA, on Tuesday 4th April, a poster session titled “Clinical Laboratory and Imaging Correlates” took place.
One of the posters on display (3724 / 9) was titled “PDL1 protein expression and tumor mutation burden in hematologic malignancies: correlation with Hodgkin and high grade lymphoma” by Lina Abdul Karim, from MedStar Georgetown University Hospital, Washington DC, and colleagues.
Immunostaining using the FDA approved PD-L1 IHC 22C3 pharmDx assay was carried out on formalin fixed paraffin embedded sections from 92 hematological malignancies including Hodgkin Lymphoma (HL), Diffuse Large B-Cell Lymphoma (DLBCL), Low-Grade Non-Hodgkin Lymphoma (LGNHL), as well as Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), and Myeloma. Partial or complete membrane staining in all viable tumor cells was scored as follows: <1% negative, 1–49% low level, and >50% high level PD-L1 expression. Comprehensive Genomic Profiling (CGP) was also done in 2,064 cases.
Key Highlights:
- High PD–L1 expression observed 100% of HL
- Significantly higher PD–L1 positivity was observed in DLBCL versus LGNHL (P = 0.01)
- In CGP analysis, Tumor Mutation Burden (TMB) was significantly higher in DLBCL versus LGNHL (P < 0.0001)
The group concluded their poster by hypothesizing that the high PD-L1 expression in HL and DLBCL, and the high TMB in DLBCL, could potentially enhance responsiveness to check point inhibitor therapy.
References